Military Infectious Disease - Prototype Innovation Program (MID-PIP)

Centivax is a universal immunity company, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that deliver universal protection against entire classes of diverse targets. The lead clinical candidate for influenza—featured in The New Yorker, the Netflix docuseries Pandemic: How to Prevent an Outbreak, and other outlets—addresses a greater than $7 billion global flu market, with follow-on programs spanning a growing pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a universal antivenom. This growing portfolio underscores the technology's broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as cancer, autoimmune conditions, cardiovascular and neurodegenerative disease. Centivax is headquartered in South San Francisco, California. Visit www.centivax.com and follow @Centivax on X.

Funding (ceiling)

$1,839,259

The University of North Carolina at Chapel Hill, the nation’s first public university, is dedicated to teaching, research, and public service. It aims to serve North Carolina, the United States, and the world by fostering a diverse community of students and preparing them to become leaders. With a commitment to excellence, UNC-Chapel Hill invests in knowledge and resources to enhance learning and improve the quality of life for all people in the state. The university is recognized for its innovative teaching, groundbreaking research, and dedication to public service, continuing a legacy that began in 1789.

Funding (ceiling)

$4,084,541

Kane Biotech is a Canadian-based biotechnology company focused on the research, development, and commercialization of products that prevent and remove microbial biofilms. Established in 2001, the company aims to improve human and animal welfare through innovative solutions to biofilm-related challenges and antimicrobial resistance. With a strong portfolio of 54 patents and patents pending, Kane Biotech is recognized as a leader in biofilm research and technology, and is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTC Markets under the symbol 'KNBIF'.

Funding (ceiling)

$3,077,247